

In the Elected Claims:

Please cancel claims 1-120, without prejudice or disclaimer to Applicants' rights to pursue the subject matter of these canceled claims in one or more duly filed divisional applications.

Add new claims 126-155 as follows:

-- 126. (NEW) A transplantation process for preventing or reducing immunological rejection in a recipient subject comprising the steps of:

transplanting into a recipient subject cells, tissues, organs, or components thereof; and

establishing selective down immune regulation in said recipient transplant subject to one or more native or non-native antigens or a mixture of native and non-native antigens. --

-- 127. (NEW) The process of claim 126, wherein said native or non-native antigens comprise hematopoietic cells. --

-- 128. (NEW) The process of claim 127, wherein said hematopoietic cells are selected from the group consisting of stem cells, T cells, lymphocytes, bone marrow cells, CD34 + and CD45 +, or combinations of any of the foregoing. --

-- 129. (NEW) The process of claim 128, wherein said T cells comprise NK cells. --

-- 130. (NEW) The process of claim 129, wherein said T cells express NK1.1 antigens associated with oral tolerance. --

-- 131. (NEW) The process of claim 126, wherein said native or non-native antigens are derived from said recipient transplant subject or a donor, or both. --

-- 132. (NEW) The process of claim 126, wherein said non-native antigens are xenogeneic or allogeneic. --

-- 133. (NEW) The process of claim 126, wherein said native antigens comprise a member selected from the recipient transplant subject's stem cells, T cells and tissues expressing recipient antigens, or a combination of any of the foregoing. --

-- 134. (NEW) The process of claim , wherein said non-native antigens comprise stem cells or T cells from a donor. --

-- 135. (NEW) The process of claim 126, wherein said transplanting step comprises bone marrow transplantation. --

-- 136. (NEW) The process of claims 126 or 135, wherein said establishing step of SIDR in said recipient transplant subject prevents or reduces graft-versus-host (GVH) rejection. --

-- 137. (NEW) The process of claim 136, wherein said GVH rejection occurs after bone marrow transplantation or solid organ transplantation. --

-- 138. (NEW) The process of claim 126, wherein said recipient transplant subject or a donor from whom the cells, tissues or organs, or components thereof, will be transplanted, or both are subjected to one or more immune modulating treatments. --

-- 139. (NEW) The process of claim 138, wherein said immune modulating treatment comprises ablation. --

-- 140. (NEW) The process of claim 139, wherein said ablation is carried out by a means selected from the group consisting of radiation, chemical agents, and biological agents, or a combination of any of the foregoing. --

-- 141. (NEW) The process of claims 139 or 140, wherein said establishing step is carried out before, during or after said ablation. --

-- 142. (NEW) The process of claim 140, wherein said biological agents are selected from the group consisting of cytokines and antibodies, or both. --

-- 143. (NEW) The process of claim 139, wherein said immune modulating treatment is carried out as a single dosage or repeated single dosages. --

-- 144. (NEW) The process of claim 126, wherein said native or non-native antigens are selected from the group consisting of natural antigens, synthetic antigens, modified antigens, unmodified antigens, whole antigens and antigen fragments, or combinations thereof. --

-- 145. (NEW) The process of 126, wherein said group of native or non-native antigens comprise histocompatibility determinants. --

-- 146. (NEW) The process of claim 145, wherein said histocompatibility determinants comprise MHC determinants I or II, or both. --

-- 147. (NEW) The process of claim 126, wherein said native or non-native antigens are selected from the group consisting of proteins, glycoproteins, enzymes, antibodies, histocompatibility determinants, ligands, receptors, hormones, cytokines, cell membranes, cell components, viruses, viral components, viral vectors, non-viral vectors, whole cells, tissues and organs. --

-- 148. (NEW) The process of claim 147, wherein said histocompatibility determinants are MHC determinants I or II, or both. --

-- 149. (NEW) A process for preventing or reducing undesirable immunological effect to an infectious agent in a subject, comprising establishing selective down immune regulation in said subject to a either a component or components or fragments of said infectious agent, or a native antigen, or both. --

-- 150. (NEW) The process of claim 149, wherein said undesirable immunological effect is selected from the group consisting of production of undesirable antibody, cell mediated immune reaction, autoimmunity, inflammatory reaction, ligand receptor binding, cytokine production and apoptosis, or a combination of any of the foregoing. --

-- 151. (NEW) The process of claims 149 or 150, wherein said undesirable immunological effect is selected from the group consisting of Hepatitis and HIV. --

-- 152. (NEW) The process of claim 151, wherein said undesirable immunological effect is selected from the group consisting of HCV- and HBV- associated cryoglobulinemia, HCV-, HBV- and HIV-associated autoimmune disorder, HBV- and HCV-associated non-liver target organ damage. --

-- 153. (NEW) The process of claim 149, wherein said component or components or fragments are natural, synthetic or immunological equivalents. --

-- 154. (NEW) The process of claim 149, further comprising the step of treating said subject with a member selected from the group consisting of a cytokine, an antibody to a cytokine, an apoptotic agent, an anti-infectious agent, or a combination of any of the foregoing. --

-- 155. (NEW) The process of any of claims 121, 123, 125, 126 or 149, wherein said selective immune down regulation further produces one or more bystander effects. --

It is believed that each of the elected or added claims 121-155 is consonant with the Examiner's species requirement.

Entry of new claims 126-155 and examination of all of the elected and new claims of Group III (claims 121-155) is respectfully requested.

\* \* \* \* \*